ÈESKÁ UROLOGIE / CZECH UROLOGY – 4 / 2017

278 Ces Urol 2017; 21(4): 272–279 PØEHLEDOVÝ ÈLÁNEK 6. Lynch HT, Ens JA, Lynch JF. The Lynch syndrome II and urological malignancies. J Urol. 1990; 143(1): 24–28. 7. Sijmons RH, Kiemeney LA, Witjes JA, Vasen HF. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. The Journal of urology. 1998; 160(2): 466–470. 8. Mueller CM, Caporaso N, Greene MH. Familial and genetic risk of transitional cell carcinoma of the urinary tract. Urol Oncol. 2008; 26(5): 451–464. 9. Joost P, Therkildsen C, Dominguez-Valentin M, Jönsson M, Nilbert M. Urinary tract cancer in lynch syndrome; increased risk in carriers of MSH2 mutations. Urology 2015; 86(6): 1212–1217. 10. Rouprêt M, Yates DR, Comperat E, Cussenot O. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol. 2008; 54(6): 1226–1236. 11. Visser O, Adolfsson J, Rossi S, et al. Incidence and survival of rare urogenital cancers in Europe. Eur J Cancer. 2012; 48(4): 456–464. 12. Watson P, Lynch HT. The tumor spectrum in HNPCC. Anticancer Res. 1994; 14(4 B): 1635–1639. 13. Crockett DG, Wagner DG, Holmäng S, Johansson SL, Lynch HT. Upper urinary tract carcinoma in Lynch syndrome cases. J Urol. 2011; 185(5): 1627–1630. 14. Sidransky D, Frost P, Von Eschenbach A, et al. Clonal origin of bladder cancer. N Engl J Med. 1992; 326(11): 737–740. 15. van der Post RS, Kiemeney LA, LigtenbergMJ, et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. Journal of medical genetics. 2010; 47(7): 464–470. 16. Skeldon SC, Semotiuk K, Aronson M, et al. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol. 2013; 63(2): 379–385. 17. Maul JS, Warner NR, Kuwada SK, Burt RW, Cannon-Albright LA. Extracolonic cancers associated with hereditary nonpolyposis colorectal cancer in the Utah Population Database. Am J Gastroenterol. 2006; 101(7): 1591–1596. 18. Burger M, Denzinger S, Hammerschmied CG, et al. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J Mol Med (Berl). 2006; 84(10): 833–841. 19. Velasco A, Riquelme E, Schultz M, et al. Mismatch repair gene expression and genetic instability in testicular germ cell tumor. Cancer Biol Ther. 2004; 3(10): 977–982. 20. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991; 34(5): 424–425. 21. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastro- enterology. 1999; 116(6): 1453–1456. 22. Green RC, Parfrey PS, Woods MO, Younghusband HB. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst. 2009; 101(5): 331–340. 23. Piñol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005; 293(16): 1986–1994. 24. Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009; 33(11): 1639–1645. 25. Funkhouser WK, Lubin IM, Monzon FA, et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn. 2012; 14(2): 91–103.